News | October 28, 2013

Biosensors Celebrates a Year of Achievement at TCT with Expanded Product Portfolio

stents drug eluting biosensors tct 2012 transcatheter biomatrix neoflex spectrum
October 28, 2013 — Biosensors International’s expanded product portfolio offers physicians a broader range of treatment options to improve patient outcomes.
 
Since the 2012 Transcatheter Cardiovascular Therapeutics annual conference (TCT 2012), the company has revitalized its core offering with the launch of BioMatrix NeoFlex, a drug-eluting stent (DES) with exceptional performance in complex lesions and challenging anatomies. It also expanded its range of dedicated bifurcation stents with Axxess, which designed to treat larger, shorter and wider-angulated bifurcations; complemented its stent portfolio by introducing a range of drug-eluting balloon dilation catheters for the treatment of both coronary and peripheral artery disease as well as introduce BioFreedom, the world’s first polymer-free stent coated with Biolimus A9.
 
In May, Biosensors acquired functional imaging company Spectrum Dynamics, whose expertise will help cath labs determine which patients require a stent without the need for diagnostic angiography. Spectrum Dynamics’s technology is faster than conventional functional imaging, requires less contrast medium to be injected and can deliver up to 10 times the sensitivity and twice the spatial resolution.
  
“We have come further than we could possibly have imagined since last year’s TCT,” said Jeffrey Jump, president, cardiovascular division, Biosensors. “Over the last 12 months, we have revamped the leading biodegradable polymer DES, increased the applications for our specialist bifurcation stent, offered cath labs a wider choice of treatment options with a range of drug-eluting balloons and acquired technology with the potential to fundamentally change the way that interventional cardiology is practiced, so who knows what we can achieve over the next 12 months.”
 
For more information: www.biosensors.com
 

Related Content

Resolute Onyx Drug-Eluting Stent Noninferior to Polymer-Free Drug-Coated Stent With One-Month DAPT
News | Stents Drug Eluting | September 30, 2019
The first randomized trial to compare a durable polymer drug- eluting stent to a polymer-free drug-coated stent in...
Biodegradable Polymer Stent Plus Shortened DAPT Safe and Effective in Unprotected Left Main CAD
News | Stents Drug Eluting | September 30, 2019
A biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual antiplatelet therapy (DAPT)...
Superiority of Orsiro Over Xience Demonstrated in STEMI Patients
News | Stents Drug Eluting | September 05, 2019
Biotronik's ultrathin Orsiro stent demonstrated superiority over Xience with respect to target lesion failure (TLF) at...
Resolute Onyx Stent With Improved Radiographic Visibility Found to Be Safe and Effective
News | Stents Drug Eluting | October 01, 2018
October 1, 2018 — Recent results from the BIONYX randomized clinical study showed the novel, thin-strutted, polymer-c
Boston Scientific Receives FDA Approval for Eluvia Drug-Eluting Vascular Stent
Technology | Stents Drug Eluting | October 01, 2018
Boston Scientific announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA)...
Eluvia Drug-Eluting Stent Demonstrates Superior Patency in IMPERIAL Trial
News | Stents Drug Eluting | September 26, 2018
Positive 12-month data from the late-breaking IMPERIAL trial was presented at the 2018 Transcatheter Cardiovascular...
Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...